SUMMARY of alleged image fraud (+ other research misconduct)

Bharat Aggarwal (MD anderson cancer center)
Article No.1 → Antioxid Redox Signal. 2012 Mar 1;16(5):413-27.
Article No.2 → Br J Pharmacol. 2012 Feb;165(3):741-53.
Article No.3 → Biochim Biophys Acta. 2012 Jan 10. [Epub ahead of print]
Article No.4 → J Biol Chem. 2012 Jan 2;287(1):245-56.
Article No.5 → Cancer Lett. 2011 Dec 17. [Epub ahead of print] (Withdrawn)
Article No.6 → Biochem Pharmacol. 2011 Dec 15;82(12):1901-9.
Article No.7 → Biochem Pharmacol. 2011 Nov 1;82(9):1134-44. 

Article No.8 → Mol Pharmacol. 2011 Nov;80(5):889-99.
Article No.9 → Mol Pharmacol. 2011 Nov;80(5):769-81.

Article No.10 → Carcinogenesis. 2011 Sep;32(9):1372-80.
Article No.11 → Cancer Prev Res (Phila). 2011 Jul;4(7):1084-94.

Article No.12 → Int J Cancer. 2011 Jul 1;129(1):23-33.
Article No.13 → Carcinogenesis. 2011 Jun;32(6):904-12.

Article No.14 → Mol Pharmacol. 2011 Feb;79(2):279-89. 
Article No.15 → J Biol Chem. 2011 Feb 18;286(7):5546-57.
Article No.16 → Cancer Res. 2011 Jan 15;71(2):538-49.

Article No.17 → J Biol Chem. 2011 Jan 14;286(2):1134-46.
Article No.18 → J Mol Med (Berl). 2010 Dec;88(12):1243-53.
Article No.19 → J Biol Chem. 2010 Nov 12;285(46):35418-27.
Article No.20 → J Biol Chem. 2010 Oct 22;285(43):33520-8. 

Article No.21 → Mol Cancer Res. 2010 Oct;8(10):1425-36.
Article No.22 → Biochem Pharmacol. 2010 Oct 1;80(7):1021-32.
Article No.23 → J Biol Chem. 2010 Aug 27;285(35):26987-97.
Article No.24 → Mol Cancer Ther. 2010 Aug;9(8):2196-207.

Article No.25 → Biochem Pharmacol. 2010 Jun 1;79(11):1640-7. 
Article No.26 → Mol Pharmacol. 2010 May;77(5):818-27.
Article No.27 → Int J Cancer. 2010 Jul 15;127(2):257-68.

Article No.28 → Mol Cancer Res. 2010 May;8(5):751-61.
Article No.29 → Mol Cancer Ther. 2010 Apr;9(4):856-68.
Article No.30 → Cancer Res. 2010 Mar 1;70(5):1951-9
Article No.31 → J Biol Chem. 2010 Apr 9;285(15):11498-507.
Article No.32 → Biochem Pharmacol. 2010 Jan 15;79(2):218-28
Article No.33 → Cancer Res. 2009 Dec 1;69(23):8958-66.
Article No.34 → Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):534-42.
Article No.35 → Cancer Res. 2009 Aug 15;69(16):6581-9.
Article No.36 → Blood. 2009 Feb 26;113(9):2003-13.
Article No.37 → Cancer Res. 2009 Feb 15;69(4):1477-84.
Article No.38 → Mol Pharmacol. 2009 Mar;75(3):525-33.
Article No.39 → Mol Cancer Res. 2009 Jan;7(1):118-28.

Article No.40 → Cancer Res. 2008 Nov 1;68(21):8861-70.
Article No.41 → Mol Cancer Ther. 2008 Oct;7(10):3306-17.                               
Article No.42 → Cell Microbiol. 2008 Jul;10(7):1442-52.
Article No.43 → Mol Cancer Res. 2008 Jun;6(6):1059-70.
Article No.44 → Cancer Res. 2008 Jun 1;68(11):4406-15.
Article No.45 → Blood. 2008 May 15;111(10):4880-91.

Article No.46 → Mol Pharmacol. 2008 May;73(5):1549-57.
Article No.47 → Blood. 2007 Nov 15;110(10):3517-25.
Article No.48 → Oncogene. 2007 Nov 15;26(52):7324-32.
Article No.49 → Mol Cancer Res. 2007 Sep;5(9):943-55.
Article No.50 → Blood. 2007 Jun 15;109(12):5112-21.
Article No.51 → Clin Cancer Res. 2007 May 15;13(10):3024-32.
                         (Mol Cancer Ther. 2010 Feb;9(2):429-37.)
Article No.52 → Clin Cancer Res. 2007 Apr 1;13(7):2290-7.
Article No.53 → Biochem Pharmacol. 2007 Apr 1;73(7):1024-32.
Article No.54 → Blood. 2007 Apr 1;109(7):2727-35.

Article No.55 → Blood. 2007 Mar 15;109(6):2293-302.
Article No.56 → Oncogene. 2007 Mar 1;26(10):1385-97.
Article No.57 → Toxicology. 2006 Nov 10;228(1):1-15.
Article No.58 → J Immunol. 2006 Oct 15;177(8):5612-22.
Article No.59 → Mol Pharmacol. 2006 Jan;69(1):195-206.
Article No.60 → Clin Cancer Res. 2006 Jan 15;12(2):662-8.
Article No.61, 62, 63, 64, 65 → J Immunol. 2000 Nov 15;165(10):5962-9. 
                                                Cancer Res. 2000 Jul 15;60(14):3838-47.
                                                J Immunol. 2000 Jun 15;164(12):6509-19.
                                                J Immunol. 2000 Jun 1;164(11):5815-25. 
                                                J Immunol. 1999 Dec 15;163(12):6800-9.

---

Houston Chronicle paper
  →  M.D. Anderson professor under fraud probe


Retraction Watch

  →  MD Anderson investigating researcher Bharat Aggarwal over images  
  →  Retraction WatchTracking retractions as a window into the scientific processMD Anderson researcher Aggarwal loses paper in Cancer Letters

Abnormal Science Blog
  →  Like Father Like Son?
  →  From the premier cancer center in the world-part 2
  →  From the premier cancer center in the world-part 3
  →  From the premier cancer center in the world-part 4
  →  From the premier cancer center in the world-part 5
  →  From the premier cancer center in the world-part 6

---

Gautam Sethi (National University of Singapore)
Abnormal Science Blog
  → Never mind the quality, feel the width

---

See also  → Alleged image fraud at the University of Tokyo
See also  → Alleged image fraud (Michael Karin lab et al.)
See also  → Alleged image manipulation (Yanagisawa lab at Tsukuba university) 
See also  → Scientific misconduct at Tokyo Medical and Dental University (Akio Kawakami, MD)

ScienceInsider News   → Whistleblower Uses YouTube to Assert Claims of Scientific Misconduct

---

Oncogene. 2007 Nov 15;26(52):7324-32. Epub 2007 May 28.

Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha.

Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

---

gure 1C, 1D - b-actin loading control in lanes 1-4 of A, is the same as b-actin in D. 

---

Mol Cancer Res. 2008 Jun;6(6):1059-70.

Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis.

Sethi G, Ahn KS, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

---

Figure 6B - Panels B1 and B2, same images used for un-treated and TQ treated groups.

---

Mol Pharmacol. 2009 Mar;75(3):525-33. Epub 2008 Dec 22.

Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1.

Pandey MK, Sung B, Ahn KS, Aggarwal BB.

Source

Department of Experimental Therapeutics, Cytokine Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

---

Figure 1D - Lanes 3 and 4 (10 and 25 dose) are identical to Figure 1G (SCC4 +/-)

---

Mol Cancer Res. 2009 Jan;7(1):118-28.

Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1.

Kunnumakkara AB, Nair AS, Sung B, Pandey MK, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, Unit 143, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

---

Figure 2B - STAT3 loading control is identical in left and right panels (IL-6 vs. IL-6+AKBA).
Figure 4A, 4C, 5D - b-actin loading control is the same for all 3 panels.

---

Cancer Res. 2009 Aug 15;69(16):6581-9. Epub 2009 Aug 4.

Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species.

Yodkeeree S, Sung B, Limtrakul P, Aggarwal BB.

Source

Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.

---

Figure 3B - DR5 siRNA.  "Medium" and "Zerumbone + TRAIL" panels are identical.
Figure 5A - DR4 and DR5 blots, vertical seam between lanes 5 and 6.

---